Navigation Links
OpGen Announces $23.6 Million Series A Financing
Date:9/12/2007

CHL Medical Partners, Highland Capital Partners and Versant Ventures Lead

Round to Help Transform Clinical Microbiology

MADISON, Wis., Sept. 12 /PRNewswire/ -- OpGen, Inc., today announced that the company has raised $23.6 million in equity financing. The round was led by CHL Medical Partners, Highland Capital Partners and Versant Ventures, with previous investor Mason Wells also participating. In conjunction, CHL's Ron Lennox will become chairman of the Board of Directors and will also be joined on the board by Corey Mulloy and Bijan Salehizadeh from Highland, and Versant's Brian Atwood.

"We are delighted to partner with three top-tier venture firms to advance OpGen's efforts in the field of clinical microbiology, said Colin Dykes, Chief Scientific Officer of OpGen. "Each has a stellar track record and expertise in commercializing technologies for diagnostic and research applications, which will be critical as we continue to grow and expand our operations."

OpGen delivers breakthrough capabilities to identify microorganisms using a unique method to analyze DNA extracted directly from the microbial cells. "Optical Mapping" has been used by organizations worldwide for comparative genomic analysis of a range of organisms of importance to human health, including tracing the origins of food-poisoning cases such as the recent outbreak linked to contaminated spinach. With this new financing the company will develop commercial instrumentation systems for the clinical microbiology marketplace.

"Currently, clinical microbiology laboratories depend on isolating and growing microorganisms from clinical samples," stated Ron Lennox. "This is a lengthy process and provides only a simple taxonomic identification. The results are rarely timely enough to influence choice of therapy and can lead to excessive use of expensive broad-spectrum antibiotics. OpGen's new system will provide data capable of identifying bacteria down to the strain level, within a single shift."

"There is a huge unmet need for systems to rapidly and accurately diagnose clinical infections and to control nosocomial infections," added Corey Mulloy of Highland. "We believe that OpGen's technology is uniquely placed to meet this need and to transform clinical microbiology."

OpGen is actively expanding both its product development and senior management team. A retained search for a new Chief Executive Officer is currently under way.

About OpGen

OpGen is commercializing a novel single molecule DNA analysis technology, "Optical Mapping", for rapid identification and analysis of microorganisms. The system can be used to obtain detailed genetic information with no requirement for prior sequence data, PCR, cloning, or probes. Applications of the new commercial systems include clinical microbial analysis, forensic microbiology and the development of novel molecular diagnostic products. For more information, please visit http://www.opgen.com or call 603-441-8100.

About CHL Medical Partners

CHL Medical Partners (http://www.chlmedical.com) is a venture capital firm founded in 1990, managing funds with combined committed capital of more than $300 million. The company invests mainly in start-up and early stage companies in the medical sector. The principals of CHL have been associated with numerous successful companies including GeneOhm Sciences, Incyte Pharmaceuticals, Alexion, Celgene, Amicus Therapeutics, Sempercare, American Renal Associates, Genomic Health, Odyssey Healthcare and Ameripath.

About Highland Capital Partners

Highland Capital Partners was founded with the mission of helping great people build great companies. Since its inception in 1988, the firm has taken a sector-focused approach to investing in exceptional healthcare, information technology, communications and consumer companies. With $3 billion of committed capital, Highland has invested in and worked to create such firms as Archemix, Ask Jeeves, Avid Technology, CheckFree, Conor Medsystems, EXACT Sciences, Helicos BioSciences, Lycos, MapQuest, Mitotix, Odyssey Healthcare, Origin MedSystems, Renal Treatment Centers, Sybase, US Labs and VistaPrint. For more information, visit Highland's web site at http://www.hcp.com.

About Versant Ventures

Versant Ventures (http://www.versantventures.com) is a leading healthcare- focused venture capital firm specializing in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services, and healthcare information technology. Versant Ventures currently manages over $1 billion in committed capital having recently raised its third fund in November 2005, and is currently managing over 70 companies in its portfolio.


'/>"/>
SOURCE OpGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. OpGen layoffs precede another funding round
2. OpGen recruits CEO to further gene-mapping business
3. OpGen adds Thomas Pyle and James Ogle to board of directors
4. OpGen forges agreement with Japanese importer
5. OpGen completes $5 million investment round
6. OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment
7. OpGen Creates Map of Worlds Most Lethal Fungus
8. OpGen Database Helps to Reduce Bioterrorist Threat
9. Speaker announces business members of IT Task Force
10. Doyle announces technology tax credits for Berbee
11. Doyle announces new energy, global warming policies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
Breaking Biology News(10 mins):